Literature DB >> 22256820

More on hemophilia A induced by ipilimumab.

Jay Lozier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22256820     DOI： 10.1056/NEJMc1113863

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 3.  Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

Review 4.  Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.

Authors:  Ahmad Tarhini
Journal:  Scientifica (Cairo)       Date:  2013-04-17

5.  Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.